This is a working overview of peptide stability, written for readers who want more than a one-paragraph summary but less than a textbook.
Reviewed 2025-09-29. Anything still debated is marked as such rather than presented as settled.
Tesamorelin binds to growth hormone-releasing hormone receptors on the surface of pituitary somatotroph cells. This binding activates adenylate cyclase, raising intracellular cyclic AMP levels and triggering the release of growth hormone into circulation. The elevated growth hormone then stimulates hepatic production of insulin-like growth factor 1. Because the effect is mediated through the endogenous axis, secretion remains subject to feedback regulation. This distinguishes it from direct growth hormone administration, which bypasses pituitary control entirely.
Clinical investigation has focused on HIV-associated lipodystrophy, a condition in which antiretroviral therapy contributes to abnormal fat distribution. Excess visceral adipose tissue accumulates in the abdomen while peripheral fat may be lost. Tesamorelin was evaluated for reducing this visceral fat depot, with trials measuring changes in abdominal fat by imaging rather than by body weight alone. The rationale rests on the known lipolytic effects of growth hormone. Effects on visceral fat are documented, while long-term outcomes regarding cardiovascular risk remain less clearly established.
Lyophilized tesamorelin is generally stored refrigerated at temperatures between 2 and 8 degrees Celsius. The solid form is comparatively stable when kept dry and protected from light. Moisture uptake can promote aggregation and degradation, so sealed containers with desiccant are common. Researchers typically avoid repeated temperature cycling, which may stress the peptide. Documentation accompanying reference materials usually specifies a shelf life under these conditions.
Once reconstituted, the peptide is handled as a solution and is less stable than the lyophilized powder. Aqueous solutions are commonly kept cold and used within a defined period. Buffer composition and pH influence degradation rates, with extremes of acidity or alkalinity accelerating hydrolysis. Preservatives may be added in multi-dose formats to limit microbial growth. Freezing and thawing of solutions is generally avoided because it can cause precipitation or loss of activity.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Synthetic peptide | Analog of growth hormone-releasing hormone |
| Amino acid length | 44 residues | Matches the native peptide backbone |
| Molecular weight | Approximately 5135 Da | Calculated from the peptide sequence |
| Receptor target | GHRH receptor | Expressed on pituitary somatotroph cells |
| Primary studied use | Visceral fat reduction | Investigated in HIV-associated lipodystrophy |
Tesamorelin is a synthetic peptide of 44 amino acids that reproduces the sequence of human growth hormone-releasing hormone (GHRH) and carries a trans-3-hexenoyl group on its N-terminal tyrosine. That small fatty-acid modification blocks cleavage by dipeptidyl peptidase-4, the enzyme that rapidly degrades native GHRH in plasma. The result is a molecule with a longer circulating half-life than the natural hormone while retaining the same receptor target. It is supplied as a lyophilized powder for reconstitution and belongs to the broader class of GHRH analogs studied for effects on pituitary growth hormone secretion.
Development work on the compound, originally designated TH9507, focused on conditions in which reduced growth hormone signaling is thought to contribute to altered body composition. The United States Food and Drug Administration approved it in 2010 for the treatment of excess visceral abdominal fat in adults with human immunodeficiency virus infection and lipodystrophy. Later research examined other populations, including adults with mild cognitive impairment, where a large trial did not meet its primary endpoints. This mixed record illustrates how a single mechanism can produce clear effects in one setting and inconclusive results in another.
Several related peptides act on the same receptor, including sermorelin, a shorter GHRH fragment, and modified analogs such as CJC-1295 and modified GRF(1-29) that are common in research settings rather than approved products. Tesamorelin differs from growth hormone itself in that it acts upstream, prompting the pituitary to release the hormone through physiological signaling rather than supplying it directly. Terminology in the literature distinguishes GHRH analogs, growth hormone secretagogues, and recombinant growth hormone, although popular discussion often blurs these categories together. Precise naming matters when comparing study results.
Tesamorelin acts on the growth hormone-releasing hormone receptor, a G-protein-coupled receptor found on somatotroph cells in the anterior pituitary. Binding triggers a rise in intracellular cyclic AMP, which in turn opens ion channels and raises calcium concentrations, leading to release of stored growth hormone into the bloodstream. Because the peptide works through the same receptor as the body's own GHRH, the resulting secretion follows a pulsatile pattern rather than a continuous elevation. The N-terminal modification slows enzymatic breakdown, so the signal persists longer than it would with the unmodified hormone.
Growth hormone released from the pituitary stimulates the liver and other tissues to produce insulin-like growth factor 1, a stable circulating protein that serves as a practical marker of activity. Clinical studies therefore track IGF-1 concentrations alongside the hormone itself, and they commonly measure body composition with imaging rather than relying on body weight alone. Visceral adipose tissue, the fat surrounding abdominal organs, is quantified by computed tomography in the studies that supported approval. Adverse effects reported in trials include injection-site reactions, joint pain, and increases in blood glucose, which is why monitoring accompanies use.
Regulatory approval in the United States came in 2010, when the Food and Drug Administration cleared the peptide for the reduction of excess abdominal fat in adults with HIV infection and associated lipodystrophy. The decision rested mainly on two randomized phase 3 trials that enrolled roughly eight hundred patients and ran for twenty-six weeks. Participants receiving active drug showed substantially greater declines in visceral adipose tissue than those receiving placebo, while total body weight changed comparatively little. A reformulated presentation was later approved, and the product has remained a niche therapy rather than a general weight-loss agent.
Tesamorelin occupies a narrow position among agents that act on the growth hormone axis. Unlike growth hormone itself, which is given as replacement, it stimulates the pituitary to release the hormone in pulses, so the downstream increase in insulin-like growth factor 1 depends on intact somatotroph function. Other peptides in the same family include shorter GHRH fragments and synthetic secretagogues with different stability profiles. Several points remain unresolved, including whether the reduction in visceral fat translates into fewer cardiovascular events, what happens to metabolic markers after long-term use, and how the drug compares with lifestyle or surgical approaches.
{\displaystyle \overbrace {{\vphantom {\frac {}{}}}\underbrace {\frac {\partial \mathbf {u} }{\partial t}} _{\text{Variation}}+\underbrace {{\vphantom {\frac {}{}}}(\mathbf {u} \cdot \nabla )\mathbf {u} } _{\begin{smallmatrix}{\text{Convective}}\\{\text{acceleration}}\end{smallmatrix}}} ^{\text{Inertia (per volume)}}=\overbrace {{\vphantom {\frac {\partial }{\partial }}}\underbrace {{\vphantom {\frac {}{}}}-\nabla w} _{\begin{smallmatrix}{\text{Internal}}\\{\text{source}}\end{smallmatrix}}+\underbrace {{\vphantom {\frac {}{}}}\nu \nabla ^{2}\mathbf {u} } _{\text{Diffusion}}} ^{\text{Divergence of stress}}+\underbrace {{\vphantom {\frac {}{}}}\mathbf {g} } _{\begin{smallmatrix}{\text{External}}\\{\text{source}}\end{smallmatrix}}.}
=== Cleaning and water softening === A chelating agent is the main component of some rust removal formulations. Citric acid is used to soften water in soaps and laundry detergents. A common synthetic chelator is EDTA. Phosphonates are also well-known chelating agents. Chelators are used in water treatment programs and specifically in steam engineering. Although the treatment is often referred to as "softening", chelation has little effect on the water's mineral content, other than to make it soluble and lower the water's pH level.
It was stated that "Marxist–Leninist norms disparaged laissez-faire individualism (as when housing is determined by one's ability to pay)", and condemned "wide variations in personal wealth as the West has not" whilst emphasizing equality, by which they mean "free education and medical care, little disparity in housing or salaries, and so forth." When asked to comment on the claim that former citizens of communist states now enjoy increased freedoms, Heinz Kessler, former East German Minister of National Defence, replied: "Millions of people in Eastern Europe are now free from employment, free from safe streets, free from health care, free from social security."
Sources: en.wikipedia.org
The last TRNA validated by the small ribosomal subunit (accommodation) transfers the amino acid. It carries to the large ribosomal subunit which binds it to one of the preceding admitted TRNA (transpeptidation). The ribosome then moves to the next mRNA codon to continue the process (translocation), creating an amino acid chain. In bacterial translation, and archaeal translation, translation occurs in the cytosol, where the ribosome binds to the mRNA. In eukaryotes, translation can occur in the cytoplasm and also across the membrane of the endoplasmic reticulum through a process called co-translational translocation. In co-translational translocation, the entire ribosome–mRNA complex binds to the outer membrane of the rough endoplasmic reticulum (ER), and the new protein is synthesized and released into the ER; the newly created polypeptide can be immediately secreted or stored inside the ER for future vesicle transport and secretion outside the cell. Many types of transcribed RNA, such as TRNA, ribosomal RNA, and small nuclear RNA, do not undergo a translation into proteins. Several antibiotics act by inhibiting translation. These include Anisomycin, cycloheximide, chloramphenicol, tetracycline, streptomycin, erythromycin, and puromycin. Prokaryotic ribosomes have a different structure from that of eukaryotic ribosomes, and thus antibiotics can specifically target bacterial infections without harming a eukaryotic host's cells.
Natural hyaluronic acid rapidly degrades in vivo, which limits its effectiveness as a long-lasting injectable filler due to the lack of cross-linking chemistry. A 2019 study investigated a self-cross-linkable form of hyaluronic acid modified with gallol groups that can form a stable hydrogel in vivo through autoxidation. The technique eliminates the need for commonly used cross-linkers in hyaluronic acid fillers like BDDE. The gallol groups on the hyaluronic acid contain three hydroxyl groups on the benzene ring, allowing for spontaneous oxidative crosslinking in vivo without the need for additional cross-linking agents. The study confirmed that this self-cross-linkable hyaluronic acid improves pharmokinetics and the long-term performance of the filler compared to non-cross-linked forms of hyaluronic acid. Self-cross-linkable hyaluronic acid is proposed for use in applications such as tissue augmentation and wrinkle correction. Other studies report that hyaluronic acid is used for tissue engineering as well as drug delivery mechanisms. Polylactic Acid
Netter, Frank H. (1987), Musculoskeletal system: anatomy, physiology, and metabolic disorders, Summit, New Jersey: Ciba-Geigy Corporation Jaffe, N.; et al. (2009). Pediatric and Adolescent Osteosarcoma. New York: Springer. ISBN 978-1-4419-0283-2.
Sources: en.wikipedia.org
In number theory, the crank of a partition is a certain integer associated with the partition. Dyson first introduced the term without a definition in a 1944 paper in a journal published by the Mathematics Society of Cambridge University. He then gave a list of properties this yet-to-be-defined quantity should have. In 1988, George E. Andrews and Frank Garvan discovered a definition for the crank satisfying the properties Dyson had hypothesized.
=== Versions === Chili mac has been a staple dish at American military dining facilities for years. It was introduced to the Meal, Ready-to-Eat (MRE) field ration menu in 1995 and is one of only three of the twelve MRE meals offered in 1995 that has remained on the MRE menu to date. A variation called "taco chili mac" has been consumed by NASA astronauts in space. It is processed by NASA as a freeze-dried product. Hamburger Helper sells a boxed version named "Chili Macaroni".
Acquired progressive lymphangioma (benign lymphangioendothelioma) Acral fibrokeratoma (acquired digital fibrokeratoma, acquired periungual fibrokeratoma) Acrochordon (cutaneous papilloma, cutaneous tag, fibroepithelial polyp, fibroma molluscum, fibroma pendulum, papilloma colli, skin tag, soft fibroma, Templeton skin tag) Adenoma sebaceum Adult type of generalized eruption of cutaneous mastocytosis African cutaneous Kaposi sarcoma African lymphadenopathic Kaposi sarcoma Aggressive infantile fibromatosis AIDS-associated Kaposi sarcoma Ainhum (bankokerend, dactylolysis spontanea, sukhapakla) Angiofibroma Angiokeratoma Angiokeratoma of Fordyce (angiokeratoma of the scrotum and vulva) Angiokeratoma of Mibelli (Mibelli's angiokeratoma, telangiectatic warts) Angioleiomyoma (vascular leiomyoma) Angiolipoleiomyoma Angiolipoma Angioma serpiginosum Angiosarcoma Aponeurotic fibroma (calcifying aponeurotic fibroma, juvenile aponeurotic fibroma) Atypical fibroxanthoma Benign lipoblastomatosis (embryonic lipoma) Buschke–Ollendorff syndrome (dermatofibrosis lenticularis disseminata) Capillary aneurysms Carcinoid Cellular angiofibroma Cherry angioma (De Morgan spot, senile angioma) Chondrodermatitis nodularis chronica helicis (chondrodermatitis nodularis helicis) Chondroid lipoma Chordoma Classic Kaposi sarcoma Collagenous fibroma (desmoplastic fibroblastoma) Composite hemangioendothelioma Connective tissue nevus (collagenoma, elastoma, shagreen patch) Cutaneous endometriosis Cutaneous meningioma (heterotopic meningeal tissue, rudimentary meningocele) Cutaneous myelofibrosis Cutaneous myxoma Cutis marmorata telangiectatica congenita (congenital generalized phlebectasia, Van Lohuizen syndrome) Dermal dendrocyte hamartoma Dermatofibroma (benign fibrous histiocytoma, dermal dendrocytoma, fibrous dermatofibroma, fibrous histiocytoma, fibroma simplex, histiocytoma, nodular subepidermal fibrosis, sclerosing hemangioma) Dermatofibrosarcoma protuberans Desmoid tumor Diffuse cutaneous mastocytosis Diffuse infantile fibromatosis Dupuytren's contracture (Dupuytren's diathesis, Dupuytren's disease, palmar fibromatosis) Eccrine angiomatous hamartoma Elastofibroma dorsi Endovascular papillary angioendothelioma (Dabska tumor, Dabska-type hemangioendothelioma, hobnail hemangioendothelioma, malignant endovascular papillary angioendothelioma, papillary intralymphatic angioendothelioma) Epithelioid cell histiocytoma Epithelioid hemangioendothelioma Epithelioid sarcoma Erythrodermic mastocytosis Extraskeletal chondroma (chondroma of soft parts) Familial myxovascular fibromas Fascial hernia Fibroma of tendon sheath Fibromatosis colli (sternomastoid tumor of infancy) Fibrous hamartoma of infancy Fibrous papule of the nose (benign solitary fibrous papule, fibrous papule of the face) Folded skin with scarring (Michelin tire baby syndrome) Fordyce's spot (Fordyce's disease) Ganglion cyst Ganglioneuroma Gardner fibroma Genital leiomyoma (dartoic leiomyoma) Giant cell fibroblastoma Giant cell tumor of the tendon sheath (giant cell synovioma, localized nodular tenosynovitis, pigmented villonodular synovitis) Glomeruloid hemangioma Glomus tumor (glomangioma, solid glomus tumor, solitary glomus tumor) Granular cell tumor (Abrikossoff's tumor, Abrikossov's tumor, granular cell myoblastoma, granular cell nerve sheath tumor, granular cell schwannoma) Hamartoma Hemangiopericytoma Hemangiosarcoma Hibernoma (fetal lipoma, lipoma of embryonic fat, lipoma of immature adipose tissue) Hypertrophic scar Immunosuppression-associated Kaposi sarcoma Infantile digital fibromatosis (inclusion body fibromatosis, infantile digital myofibroblastoma, Reye tumor) Infantile hemangiopericytoma (congenital hemangiopericytoma) Infantile myofibromatosis (congenital generalized fibromatosis, congenital multicentric fibromatosis) Infantile systemic hyalinosis (juvenile systemic hyalinosis) Intradermal spindle cell lipoma Intravascular papillary endothelial hyperplasia (Masson's hemangio-endotheliome vegetant intravasculaire, Masson's lesion, Masson's pseudoangiosarcoma, Masson's tumor, papillary endothelial hyperplasia) Juvenile hyaline fibromatosis (fibromatosis hyalinica multiplex juvenilis, Murray–Puretic–Drescher syndrome) Kaposiform hemangioendothelioma (infantile kaposiform hemangioendothelioma) Kasabach–Merritt syndrome (hemangioma with thrombocytopenia) Keloid (Keloidal scar) Keratinizing metaplasia Keratocyst Klippel–Trenaunay syndrome (angioosteohypertrophy syndrome, hemangiectatic hypertrophy) Knuckle pads (heloderma) Leiomyosarcoma Lipoma Liposarcoma (atypical lipoma, atypical lipomatous tumor) Lymphangiectasis (lymphangioma) Lymphangiomatosis Malignant fibrous histiocytoma Malignant peripheral nerve sheath tumor (malignant schwannoma, neurofibrosarcoma, neurosarcoma) Mast cell sarcoma Meningocele Metastatic carcinoma Microvenular hemangioma (microcapillary hemangioma) Midline nevus flammeus (angel's kiss, salmon patch) Multifocal lymphangioendotheliomatosis (congenital cutaneovisceral angiomatosis with thrombocytopenia, multifocal lymphangioendotheliomatosis with thrombocytopenia) Multinucleate cell angiohistocytoma Multiple cutaneous and uterine leiomyomatosis syndrome (leiomyomatosis cutis et uteri, multiple leiomyomatosis, Reed's syndrome) Multiple cutaneous leiomyoma (pilar leiomyoma) Neural fibrolipoma Neuroblastoma (infantile neuroblastoma, neuroepithelioma) Neuroma cutis Neurothekeoma (bizarre cutaneous neurofibroma, cutaneous lobular neuromyxoma, myxoma of the nerve sheath, myxomatous perineurioma, nerve sheath myxoma) Nevus flammeus (capillary malformation, port-wine stain) Nevus flammeus nuchae (stork bite) Nevus lipomatosus superficialis (nevus lipomatosis of Hoffman and Zurhelle) Nevus oligemicus Nodular fasciitis (nodular pseudosarcomatous fasciits, pseudosarcomatous fasciitis, subcutaneous pseudosarcomatous fibromatosis) Oral submucous fibrosis Pachydermodactyly Palisaded encapsulated neuroma Paraneoplastic syndrome Pearly penile papules (hirsuties coronae glandis, hirsutoid papillomas) Peyronie's disease (induratio penis plastica) Phakomatosis pigmentovascularis Piloleiomyoma Plantar fibromatosis (Ledderhose's disease) Pleomorphic fibroma Pleomorphic lipoma Plexiform fibrohistiocytic tumor Porokeratotic eccrine ostial and dermal duct nevus Progressive nodular histiocytoma Proliferating angioendotheliomatosis Prominent inferior labial artery Pseudo-ainhum
Sources: en.wikipedia.org
It is a synthetic analog of growth hormone-releasing hormone, a hypothalamic peptide. It functions as a growth hormone secretagogue acting at pituitary receptors. The classification separates it from direct growth hormone products.
The synthetic peptide incorporates modifications that slow enzymatic breakdown in circulation. Native growth hormone-releasing hormone is short-lived, whereas the analog is designed for greater stability. The core amino acid backbone is largely retained.
The main studied application is reduction of excess visceral abdominal fat in HIV-associated lipodystrophy. Research has measured fat changes through imaging. Findings concern fat distribution rather than overall body weight.
Refrigeration between 2 and 8 degrees Celsius is typical, with protection from moisture and light. Dry, sealed containers help maintain stability over the labeled shelf life. Temperature cycling is usually minimized.